(June 16, live report in Stockholm) On behalf of Beijing Boren Hospital, Director Jing PAN in the Department of Hematology in our hospital delivered a speech at the 23rd annual conference of the European Hematology Association (EHA) held in Stockholm, Sweden, and reported the results of the clinical study on humanized CD22-CART cell therapy in 15 children with refractory/relapsed B-cell acute lymphoblastic leukemia (B-ALL). Among them, 14 patients previously received CD19-CART therapy but had no response or relapsed, and 1 patient had weak expression of CD19 in leukemia cells, so CD22-CART was selected for salvage treatment. Four of the 15 patients relapsed after allogeneic hematopoietic stem cell transplantation (Allo-HSCT). After CD22-CART therapy, 86.7% of patients had response, and 80% of them achieved complete remission. Six patients achieving complete remission underwent bridging Allo-HSCT. The 6-month progression-free survival rate in the patients with response to CD22-CART therapy was 91.7%. No deaths and serious complications occurred during the CD22-CART therapy, and the cytokine release syndrome was only mild to moderate (grade 0-2). In our hospital, humanized CD22-CART therapy achieved significant efficacy and had mild side effects in the treatment of refractory/relapsed B-ALL, reaching the internationally advanced level.
It was even more proud that before the conference, Director Jing PAN was also invited by the EHA Organizing Committee to attend the press conference and became one of the three speakers at the press conference to accept on-site interview and exclusive interview from dozens of media around the world.
In our hospital, humanized CD22-CART therapy achieved significant efficacy and had mild side effects in the treatment of refractory/relapsed B-ALL, so it is a new life-saving and effective treatment method for patients with no response to CD19-CART therapy and with weak or no expression of CD19 in leukemia cells, and it has a good prospect of application.
For the oral speech included in the EHA, Director Jing PAN said that academic research is a systematic project that relies heavily on the team and requires long-term investment, but not a simple job of someone in a short time, and there is no shortcut on the road of scientific research. Under the leadership of the principal investigator, Director Chunrong TONG, this clinical study was completed by the efforts of laboratory and clinical staff, including the provider of CAR Professor Zhang Hongsheng, the cell preparation team led by Director Deng Biping, the team of hematology led by Director Liu Shuangyou and Director Jing PAN and the transplantation team led by Director Wu Tong and Director Gao Zhiyong. Honor belongs to the collective and belongs to all the hard-working medical staff!
What we are seeing is the rigorous academic attitude of Beijing Boren Hospital, the team spirit of sincere cooperation and the academic soil for new stars. In the future, Beijing Boren Hospital will make more high-quality clinical researches to demonstrate its strength in academic fields at home and abroad and bring new hope to patients!
Principal Investigator Director Chunrong TONG
Cell Preparation Team
The Eighth Ward in Department of Hematology Led by Dr. Jing PAN